Countless things can go wrong in the complicated cell division process. Checkpoints fail, genomic instability increases, and when anarchy reigns, cancers spread. In trying to assess what is doing the damage and predict the damage yet to be done, doctors have an admittedly blunt set of tools to profile renegade cells. Histopathology and general prognostic indicators such as health, age, and metastatic spread do little to account for the breadth of tumor variety even within fairly specialized tumor types.